These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 25169507)

  • 1. Elevated PIVKA-II is associated with early recurrence and poor prognosis in BCLC 0-A hepatocellular carcinomas.
    Wang BL; Tan QW; Gao XH; Wu J; Guo W
    Asian Pac J Cancer Prev; 2014; 15(16):6673-8. PubMed ID: 25169507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival outcomes of hepatectomy for stage B Hepatocellular carcinoma in the BCLC classification.
    Kamiyama T; Orimo T; Wakayama K; Shimada S; Nagatsu A; Yokoo H; Kamachi H; Yamashita K; Shimamura T; Taketomi A
    World J Surg Oncol; 2017 Aug; 15(1):156. PubMed ID: 28830473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor marker levels before and after curative treatment of hepatocellular carcinoma as predictors of patient survival.
    Nanashima A; Taura N; Abo T; Ichikawa T; Sakamoto I; Nagayasu T; Nakao K
    Dig Dis Sci; 2011 Oct; 56(10):3086-100. PubMed ID: 21706206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of PIVKA-II After Living-donor Liver Transplantation for Hepatocellular Carcinoma.
    Park MS; Lee KW; Kim H; Choi YR; Hong G; Yi NJ; Suh KS
    Transplant Proc; 2017 Jun; 49(5):1109-1113. PubMed ID: 28583537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA.
    Wu J; Xiang Z; Bai L; He L; Tan L; Hu M; Ren Y
    Cancer Biomark; 2018; 23(2):235-242. PubMed ID: 30103302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma.
    Lee S; Rhim H; Kim YS; Kang TW; Song KD
    Liver Int; 2016 Apr; 36(4):580-7. PubMed ID: 26503910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection.
    Kim DY; Paik YH; Ahn SH; Youn YJ; Choi JW; Kim JK; Lee KS; Chon CY; Han KH
    Oncology; 2007; 72 Suppl 1():52-7. PubMed ID: 18087182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients.
    Meguro M; Mizuguchi T; Nishidate T; Okita K; Ishii M; Ota S; Ueki T; Akizuki E; Hirata K
    World J Gastroenterol; 2015 Apr; 21(16):4933-45. PubMed ID: 25945007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NX-PVKA levels before and after hepatectomy of hepatocellular carcinoma as predictors of patient survival: a preliminary evaluation of an improved assay for PIVKA-II.
    Nanashima A; Abo T; Taura N; Shibata H; Ichikawa T; Takagi K; Arai J; Oyama S; Nagayasu T
    Anticancer Res; 2013 Jun; 33(6):2689-97. PubMed ID: 23749928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative tumor marker doubling time is a useful predictor of recurrence and prognosis after hepatic resection of hepatocellular carcinoma.
    Masuda T; Beppu T; Horino K; Komori H; Hayashi H; Okabe H; Otao R; Horlad H; Ishiko T; Takamori H; Kikuchi K; Baba H
    J Surg Oncol; 2010 Oct; 102(5):490-6. PubMed ID: 19937994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIVKA-II combined with tumor burden score to predict long-term outcomes of AFP-negative hepatocellular carcinoma patients after liver resection.
    Qiu ZC; Wu YW; Qi WL; Li C
    Cancer Med; 2024 Jan; 13(1):e6835. PubMed ID: 38130028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological risk factors for recurrence within one year after initial hepatectomy for hepatocellular carcinoma.
    Hayashi M; Shimizu T; Hirokawa F; Inoue Y; Komeda K; Asakuma M; Miyamoto Y; Takeshita A; Shibayama Y; Tanigawa N
    Am Surg; 2011 May; 77(5):572-8. PubMed ID: 21679590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient Selection by Tumor Markers in Liver Transplantation for Advanced Hepatocellular Carcinoma.
    Lee HW; Song GW; Lee SG; Kim JM; Joh JW; Han DH; Kim SI; Kim SH; Kim DS; Cho JY; Suh KS
    Liver Transpl; 2018 Sep; 24(9):1243-1251. PubMed ID: 29575509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
    Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
    J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prothrombin induced by vitamin K Absence-II versus alpha-fetoprotein in detection of both resectable hepatocellular carcinoma and early recurrence after curative liver resection: A retrospective cohort study.
    Wang MD; Sun LY; Qian GJ; Li C; Gu LH; Yao LQ; Diao YK; Pawlik TM; Lau WY; Huang DS; Shen F; Yang T
    Int J Surg; 2022 Sep; 105():106843. PubMed ID: 35995351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of tumor markers in patients with recurrent hepatocellular carcinoma in different vascular invasion pattern.
    Gao F; Zhu HK; Zhu YB; Shan QN; Ling Q; Wei XY; Xie HY; Zhou L; Xu X; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2016 Aug; 15(4):371-7. PubMed ID: 27498576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.
    Feng H; Li B; Li Z; Wei Q; Ren L
    BMC Cancer; 2021 Apr; 21(1):401. PubMed ID: 33849479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein.
    Suehiro T; Sugimachi K; Matsumata T; Itasaka H; Taketomi A; Maeda T
    Cancer; 1994 May; 73(10):2464-71. PubMed ID: 7513601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion.
    Poté N; Cauchy F; Albuquerque M; Voitot H; Belghiti J; Castera L; Puy H; Bedossa P; Paradis V
    J Hepatol; 2015 Apr; 62(4):848-54. PubMed ID: 25450201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic analysis of stage II-III hepatocellular carcinoma showing early massive recurrence after liver resection.
    Yamanaka J; Yamanaka N; Nakasho K; Tanaka T; Ando T; Yasui C; Kuroda N; Takata M; Maeda S; Matsushita K; Uematsu K; Okamoto E
    J Gastroenterol Hepatol; 2000 Oct; 15(10):1192-8. PubMed ID: 11106101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.